Skip to main content
. 2017 Jan 12;10(3):213–220. doi: 10.21053/ceo.2016.01263

Fig. 3.

Fig. 3.

Expression of (A) Ki-67 in invasive, (B) Ki-67 in noninvasive, (C) cytokeratin 17 (CK17) in invasive, and (D) CK17 in noninvasive cholesteatoma. Overexpression of Ki-67 is observed in the invasive group as compared to the noninvasive one (arrows). The same is true for CK17 (arrows) (Mayer’s hematoxylin, ×200).